Skye Bioscience, Inc.
Public company- Headquarters
- SAN DIEGO, California
- Ticker
- SKYE
- CIK
- 0001516551
WARN notices since 2024
Workers affected since 2024
Executive changes, last 12 months
Last event
Workers affected over time
Cumulative workers in WARN notices since 2024
Not enough notices to chart yet.
Leadership
| Role and person | Since | Change |
|---|---|---|
| CFOJohn P. Sharp | Sep 11, 2026 | Departed |
| principal financial and accounting officerPunit Dhillon | Sep 11, 2026 | Appointed |
Related companies
Same industry and state, with recent events.
- ACADIA PHARMACEUTICALS INC
Executive Vice President, Head of Research and Development departs: Elizabeth H.Z. Thompson, Ph.D.
- KYNTRA BIO, INC.
Class III director appointed: Andrew E. Singer, MBA
- BIOMARIN PHARMACEUTICAL INC
WARN notice: Novato, CA
- CORCEPT THERAPEUTICS INC
President of Corcept Endocrinology departs: Sean Maduck
- Executive departure
CFO departs: John P. Sharp
John P. Sharp, Chief Financial Officer and principal financial and accounting officer of Skye Bioscience, Inc., resigns the role. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 11, 2026Role: Chief Financial Officer and principal financial and accounting officer
- Executive appointment
principal financial and accounting officer appointed: Punit Dhillon
Punit Dhillon was named principal financial and accounting officer of Skye Bioscience, Inc., effective September 8, 2026. Punit Dhillon succeeds John P. Sharp. The company reported the change in an 8-K that cites Item 5.02.
Source: SEC 8-K, filed Sep 11, 2026Role: principal financial and accounting officer
Last verified Nov 8, 2026